Table 3.

Comparison of KRAS G12C Inhibitors for NSCLC

	CodeBreak 100	CodeBreak 100	CodeBreak 200	KRYSTAL-1	NCT04449874
Phase	I	II	III	I-III	I
Drug	Sotorasib	Sotorasib	Sotorasib v docetaxel	Adagrasib	Divarasib
Number NSCLC patients	59	126	171 v 174	112
ORR	32.2%	37.1%	28.1% v 13.2%	43%	53.4%
DOR (months)	10.9	11.1	8.36 v 6.8	8.5	14.0
PFS (months)	6.3	6.8	5.6 v 4.5	6.5	13.1
OS (months)	N/A	12.5	10.6 v 11.3	12.6	N/A